ASLAN Pharmaceuticals Limited (ASLN)

0.5400 +0.0490 (+9.98%) At close: 04:00PM EDT

ASLAN Pharmaceuticals Limited

3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
Singapore
65 6817 9598
https://aslanpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.	Founder, CEO & Executive Director	N/A	N/A	1973
Mr. Kiran Kumar Asarpota	COO & Head of Finance	N/A	N/A	1979
Mr. Ben Goodger	General Counsel	N/A	N/A	1963
Mr. Stephen Doyle	Chief Business Officer	N/A	N/A	1973
Dr. Alexandre Kaoukhov M.D.	Chief Medical Officer	N/A	N/A	1974
Charlie Hsu	Investor Relations Director	N/A	N/A	N/A
Chi-Chin Wang	IR & Corporate Development Director	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Corporate governance

ASLAN Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.